UBS analyst Laura Sutcliffe upgraded Sanofi to Buy from Neutral and raised her price target for the shares to 87 euros from 79 euros. The analyst sees signs of a turnaround for the company and believes its pipeline can fixed ahead of patent expiration. She expects mid-single-digit sales growth for rate diseases and vaccines through 2023 as well as success for Dupixent.
Get caught up quickly on the top news and calls moving stocks with these five Top Five lists. 1... To see the rest of the story go to thefly.com. See Story Here